Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB2 | P47870 | 2/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24610569 | 0.88 | GABRB2 (0.36) | GABRB2GABRA1POLBHTR1DALOX5AP | |
| SCHEMBL1040694 | 0.88 | POLB (0.43) | GABRB2GABRA1POLBHTR1DALOX5AP | |
| SCHEMBL1042661 | 0.86 | GABRA1 (0.34) | GABRB2GABRA1POLBHTR1DALOX5AP | |
| SCHEMBL3944248 | 0.84 | ALOX15 (0.36) | POLBAKR1C3AKR1C2ALDH1A1HPGD | |
| SCHEMBL22861248 | 0.81 | CYP2C19 (0.35) | GABRB2GABRA1HTR1DAKR1C3AKR1C2 | |
| SCHEMBL24610551 | 0.78 | GABRB2 (0.36) | GABRB2GABRA1POLBHTR1DALOX5AP | |
| SCHEMBL7847209 | 0.78 | GABRA1 (0.43) | GABRB2GABRA1POLBHTR1DALOX5AP | |
| SCHEMBL12390583 | 0.76 | POLB (0.44) | GABRB2GABRA1POLBHTR1DALOX5AP | |
| SCHEMBL7922004 | 0.76 | ALDH1A1 (0.45) | GABRB2GABRA1ALDH1A1HPGDALOX15 | |
| SCHEMBL10212115 | 0.76 | GABRA1 (0.42) | GABRB2GABRA1POLBHTR1DALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20240228514-A1 | BORON-CONTAINING ORGANIC COMPOUND AND APPLICATIONS THEREOF | SHENZHEN CHINA STAR OPTOELECTRONICS SEMICONDUCTOR DISPLAY TECHNOLOGY CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240228514-A1 | BORON-CONTAINING ORGANIC COMPOUND AND APPLICATIONS THEREOF | SHENZHEN CHINA STAR OPTOELECTRONICS SEMICONDUCTOR DISPLAY TECHNOLOGY CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-09-21 | — | — | US | disclosed |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-09-21 | — | — | US | disclosed |
| US-20230128198-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230128198-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230002390-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-01-05 | — | — | US | disclosed |
| US-11384066-B1 | Heterocyclic compounds useful as aurora a selective inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228514-A1 | BORON-CONTAINING ORGANIC COMPOUND AND APPLICATIONS THEREOF | BCL6, SLCO4C1, SLCO2B1 | GABRB2 377/4885GABRA1 707/4885POLB 2356/4885 |
| US-20230002390-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | GABRB2 355/4885GABRA1 384/4885POLB 4764/4885 |
| US-11384066-B1 | Heterocyclic compounds useful as aurora a selective inhibitors | AURKA, AURKC, AURKB | GABRB2 4639/4885GABRA1 4504/4885POLB 1600/4885 |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | GABRB2 3910/4885GABRA1 3438/4885POLB 624/4885 |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | HCCS, HAVCR2, HDGF | GABRB2 2308/4885GABRA1 2255/4885POLB 395/4885 |
| US-20230128198-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS | AURKA, AURKC, AURKB | GABRB2 4674/4885GABRA1 4455/4885POLB 2327/4885 |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | GABRB2 355/4885GABRA1 384/4885POLB 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.